SAN DIEGO--(BUSINESS WIRE)--On January 9 th 2023, CRISPR QC has announced that they have closed their Seed Round at $1.6M and appoints George Bonaros to Board of Directors to fuel commercial growth of ...
CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead asset and multiple upcoming ...
The company's innovative qualities may pay rich dividends down the road.
CRISPR Therapeutics' biggest milestone came in late 2023, when CASGEVY, the gene-editing therapy it developed alongside Vertex Pharmaceuticals (VRTX +0.89%), became the first CRISPR-based treatment ...
SAN DIEGO--(BUSINESS WIRE)--CRISPR QC, a biotechnology start-up based in San Diego, is pleased to announce a major stride in its ongoing Series A funding round. Known for their CRISPR Analytics ...
Crispr Therapeutics’ first-quarter results align with our expectations, and its early-stage pipeline candidates are advancing in clinical trials. We continue to expect 2024 will be a pivotal year as ...
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.
BASEL, Switzerland, CAMBRIDGE, Mass., and GAITHERSBURG, Md., March 14, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative ...
Soilcea has started commercial shipments of its CRISPR-developed CarriCea T1 citrus rootstock following approval.
CRISPR Therapeutics (NasdaqGM:CRSP) has come under pressure after a six day losing streak that cut the stock by about 18%, ...
1mon
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results